TOZARIDE
Live / Registered — Registered — Section 8 accepted (as of 08 Jul 2025)
What this means for you
Registered since 08 Jan 2019. The owner can stop confusingly similar uses in the classes it covers.
Record
- Serial number
- 87691768
- Registration number
- 5650970
- Mark type
- Stylized text
- Filed
- 20 Nov 2017
- Published for opposition
- 17 Apr 2018
- Registered
- 08 Jan 2019
Goods and services
- Class 005 — Pharmaceuticals: Peptide-based pharmaceutical preparations for the treatment of lung cancer
Owner
- Andarix Pharmaceuticals, Inc., Somerville, MA, US
- Andarix Pharmaceuticals, Inc., Somerville, MA, US
- Andarix Pharmaceuticals, Inc., Somerville, MA, US
Prosecution history
- 08 Jul 2025 — NOTICE OF ACCEPTANCE OF SEC. 8 - E-MAILED
- 08 Jul 2025 — REGISTERED - SEC. 8 (6-YR) ACCEPTED
- 11 Jun 2025 — TEAS RESPONSE TO OFFICE ACTION-POST REG RECEIVED
- 16 May 2025 — POST REGISTRATION ACTION MAILED - SEC. 8
- 16 May 2025 — CASE ASSIGNED TO POST REGISTRATION PARALEGAL
- 02 Jan 2025 — TEAS SECTION 8 RECEIVED
- 08 Jan 2024 — COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED
- 08 Jan 2019 — REGISTERED-PRINCIPAL REGISTER
- 07 Dec 2018 — NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
- 06 Dec 2018 — ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
- 03 Dec 2018 — STATEMENT OF USE PROCESSING COMPLETE
- 16 Nov 2018 — USE AMENDMENT FILED
- 03 Dec 2018 — CASE ASSIGNED TO INTENT TO USE PARALEGAL
- 16 Nov 2018 — TEAS STATEMENT OF USE RECEIVED
- 12 Jun 2018 — NOA E-MAILED - SOU REQUIRED FROM APPLICANT